Penumbra (PEN) vs ResMed (RMD)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Penumbra (PEN) has outperformed ResMed (RMD) over the past year, gaining 27.0% versus a loss of 20.2%. Over five years, PEN leads with a +18.2% price change compared with -11.6% for RMD. ResMed is the larger company by market cap ($31.89 billion vs $12.51 billion), about 2.5 times the size, while Penumbra is growing revenue faster (+17.5% vs +9.9%).
On valuation, ResMed trades at a lower forward P/E (17.1x vs 51.8x for Penumbra). ResMed pays a dividend yielding 1.06%, while Penumbra does not currently pay one. ResMed converts more of its revenue into profit, with a net margin of 26.9% versus 12.7%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | PEN | RMD |
|---|---|---|
| Share price | $317.52 | $226.73 |
| Market cap | $12.51B | $31.89B |
| 1-day change | +0.37% | +0.33% |
| YTD return | +1.75% | -6.18% |
| 1-year return | +27.03% | -20.23% |
| 5-year return | +18.15% | -11.55% |
| P/E ratio (TTM) | 78.01 | 21.74 |
| Forward P/E | 51.78 | 17.14 |
| EPS (TTM) | $4.07 | $10.43 |
| Dividend yield | 0.00% | 1.06% |
| Annual dividend | $0.00 | $2.40 |
| Revenue (latest FY) | $1.40B | $5.65B |
| Revenue growth (YoY) | +17.50% | +9.85% |
| Net income (latest FY) | $177.69M | $1.52B |
| Gross margin | 67.14% | 61.06% |
| Operating margin | 13.48% | 33.37% |
| Net margin | 12.66% | 26.94% |
| 52-week high | $362.41 | $284.05 |
| 52-week low | $221.26 | $180.27 |
| Distance from 52-week high | -12.39% | -20.18% |
| Analyst consensus | hold | buy |
| Avg. price target upside | +13.88% | +10.36% |
| Average volume | 344.71K | 1.34M |
| Shares outstanding | 39.39M | 140.64M |
| Employees | 4,700 | 11,370 |
| Sector | Health Care | Health Care |
| Industry | Medical/Dental Instruments | Medical/Dental Instruments |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ResMed is about 2.5 times larger than Penumbra by market value ($31.89B vs $12.51B).
- PEN has outperformed RMD by 47.3 percentage points over the past year.
- Penumbra trades at a higher earnings multiple (78.0x vs 21.7x trailing P/E).
- ResMed offers a meaningfully higher dividend yield (1.06% vs 0.00%).
- ResMed is more profitable, keeping 26.9 cents of every revenue dollar as net income versus 12.7 cents for Penumbra.
- Penumbra grew revenue faster in its latest fiscal year (+17.50% vs +9.85%).
About Penumbra
PEN stock →Penumbra, Inc., together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. It offers computer-assisted vacuum thrombectomy; peripheral thrombectomy products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX.
Health Care · Medical/Dental Instruments · 4,700 employees
About ResMed
RMD stock →ResMed Inc. engages in the digital health and cloud-connected medical devices business in the United States and internationally.
Health Care · Medical/Dental Instruments · 11,370 employees
PEN vs RMD FAQ
Which is bigger, Penumbra or ResMed?
ResMed (RMD) is larger, with a market capitalization of $31.89B compared with $12.51B for Penumbra (PEN).
Which stock has performed better over the past year, PEN or RMD?
PEN returned +27.03% over the past 12 months, compared with -20.23% for RMD (price return, excluding dividends). Past performance does not predict future results.
Which has the lower P/E ratio, PEN or RMD?
RMD has the lower trailing P/E at 21.7, versus 78.0 for PEN. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Which pays a higher dividend, Penumbra or ResMed?
ResMed pays a dividend yielding 1.06%, while Penumbra does not currently pay a regular dividend.
Are Penumbra and ResMed in the same industry?
Yes. Both are classified in the Medical/Dental Instruments industry within the Health Care sector.